Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06672822 · ClinicalTrials.gov registry record · Phase 2
Intralesional Injection of STS in Treatment of Calcinosis
A Phase 2 study of Dermatomyositis and Systemic Sclerosis (SSc), sponsored by Robyn T. Domsic, MD, MPH.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06672822: Recruiting Phase 2 study of Dermatomyositis and Systemic Sclerosis (SSc), sponsored by Robyn T. Domsic, MD, MPH.
NCT06672822 is a Phase 2 study of Dermatomyositis and Systemic Sclerosis (SSc) that is actively recruiting participants, run by Robyn T. Domsic, MD, MPH. The registered enrollment target is 20 participants, below the 484-participant average among 19 other Dermatomyositis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06672822, a Phase 2 study of Dermatomyositis and Systemic Sclerosis (SSc), is actively recruiting participants, sponsored by Robyn T. Domsic, MD, MPH.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
Primary Outcome
Change in size of calcinosis lesions will be measured by x-ray at baseline and then again at 12 weeks.
Conditions Studied
Interventions
- DRUG Sodium Thiosulfate (STS)
Study Locations (1)
Pennsylvania
- UPMC Arthritis and Autoimmunity Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2029-05-01 |
| Phase | Phase 2 |
What NCT06672822 shows while recruiting
NCT06672822 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 484-participant average among 19 other Dermatomyositis trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Dermatomyositis appearing as the primary indexed condition, and to 1 intervention - of which Sodium Thiosulfate (STS) is the first listed.
NCT06672822 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06672822 about?
NCT06672822 is a clinical study titled "Intralesional Injection of STS in Treatment of Calcinosis". The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients....
What is the current status of trial NCT06672822?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-03-17. Estimated completion is 2029-05-01.
What conditions does trial NCT06672822 study?
This clinical trial studies the following conditions: Dermatomyositis, Systemic Sclerosis (SSc), Calcinosis, Mixed Connective Tissue Disease (MCTD).
What interventions are being tested in trial NCT06672822?
The interventions under investigation include: Sodium Thiosulfate (STS) (DRUG).
Who is sponsoring clinical trial NCT06672822?
This trial is sponsored by Robyn T. Domsic, MD, MPH, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06672822 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatomyositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06672822's enrollment target sits among peer trials
20 17th of 19 higher than 2 of 19 other Dermatomyositis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatomyositis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RECRUITING · Phase 2
-
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
RECRUITING · Phase 2
-
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
ACTIVE NOT RECRUITING · Phase 2
-
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI